17 studies found for:    Open Studies | "Rhabdoid Tumor"
Show Display Options
Rank Status Study
1 Recruiting Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
Conditions: Malignant Rhabdoid Tumor;   Atypical Teratoid Rhabdoid Tumor
Interventions: Drug: alisertib;   Drug: methotrexate;   Drug: cisplatin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: topotecan;   Drug: vincristine;   Procedure: Surgical resection;   Radiation: Radiation therapy
2 Recruiting A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Conditions: Malignant Rhabdoid Tumors (MRT);   Rhabdoid Tumors of the Kidney (RTK);   Atypical Teratoid Rhabdoid Tumors (ATRT);   Selected Tumors With Rhabdoid Features;   Synovial Sarcoma;   INI1-negative Tumors;   Malignant Rhabdoid Tumor of Ovary
Intervention: Drug: Tazemetostat
3 Recruiting A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Conditions: Rhabdoid Tumors;   INI1-negative Tumors;   Synovial Sarcoma;   Malignant Rhabdoid Tumor of Ovary
Intervention: Drug: Tazemetostat
4 Recruiting Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Conditions: Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Rhabdoid Tumor;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Germ Cell Tumors;   Ewings Sarcoma;   Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
Interventions: Drug: Simvastatin;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Myeloid growth factor
5 Recruiting A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Conditions: Ewing Sarcoma;   Gastrointestinal Tumor;   Germ Cell Tumor;   Hepatic Tumor;   Lymphoma;   Wilms Tumor;   Rhabdoid Tumor;   Clear Cell Carcinoma;   Renal Cell Carcinoma;   Melanoma;   Neuroblastoma;   Rhabdomyosarcoma;   Non-rhabdomyosarcoma
Interventions: Drug: alemtuzumab;   Drug: fludarabine;   Drug: sirolimus;   Drug: Busulfan;   Drug: melphalan;   Biological: stem cells
6 Recruiting Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
Conditions: Clear Cell Sarcoma of the Kidney;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Rhabdoid Tumor of the Kidney;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis
7 Recruiting Study of Kidney Tumors in Younger Patients
Conditions: Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
8 Recruiting Molecular-Guided Therapy for Childhood Cancer
Conditions: Neuroblastoma;   Medulloblastoma;   Glioma;   Ependymoma;   Choroid Plexus Neoplasms;   Craniopharyngioma;   Dysembryoplastic Neuroepithelial Tumor;   Meningioma;   Primitive Neuroectodermal Tumors (PNETs);   Germ Cell Tumors;   Rhabdomyosarcoma;   Non-rhabdomyosarcoma;   Ewings Sarcoma;   Osteosarcoma;   Wilms Tumor;   Renal Cell Carcinoma;   Malignant Rhabdoid Tumor;   Clear Cell Sarcoma;   Liver Tumors
Intervention: Device: Guided Therapy
9 Not yet recruiting Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
Conditions: Diffuse Intrinsic Pontine Glioma;   Brain Tumor, Recurrent;   Solid Tumor, Recurrent;   Neuroblastoma, Recurrent, Refractory;   Ewing Sarcoma, Recurrent, Refractory;   Rhabdomyosarcoma, Recurrent, Refractory;   Osteosarcoma, Recurrent, Refractory;   Rhabdoid Tumor, Recurrent, Refractory
Intervention: Drug: Abemaciclib
10 Recruiting Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Conditions: Ewing's Family Tumors;   Renal Tumors;   Hepatoblastoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Primary Malignant Brain Neoplasms;   Retinoblastoma;   Medulloblastoma;   Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET);   Atypical Teratoid/Rhabdoid Tumor (AT/RT);   CNS Tumors;   Germ Cell Tumors
Interventions: Drug: Ifosfamide;   Drug: Etoposide;   Drug: Mesna;   Biological: G-CSF;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Leukapheresis
11 Recruiting Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma
Intervention: Other: cytology specimen collection procedure
12 Recruiting Collecting and Storing Tissue From Young Patients With Cancer
Condition: Cancer
Interventions: Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
13 Not yet recruiting HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
Condition: Supratentorial Neoplasms, Malignant
Intervention: Biological: G207
14 Unknown  Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
Conditions: Bladder Cancer;   Brain and Central Nervous System Tumors;   Esophageal Cancer;   Intraocular Melanoma;   Kidney Cancer;   Lymphoma;   Melanoma (Skin);   Pancreatic Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration
15 Recruiting Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Induction Chemotherapy;   Drug: Low-Risk Therapy;   Drug: High-Risk Therapy;   Drug: Intermediate-Risk Therapy
16 Recruiting Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Conditions: Brain and Central Nervous System Tumors;   Intraocular Melanoma;   Lung Cancer;   Melanoma (Skin);   Metastatic Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Small Intestine Cancer
Interventions: Genetic: DNA analysis;   Other: immunologic technique;   Other: pharmacological study;   Radiation: iodine I 131 monoclonal antibody 3F8;   Radiation: 131I-3F8
17 Recruiting Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Conditions: Brain and Central Nervous System Tumors;   Neuroblastoma;   Sarcoma
Intervention: Radiation: iodine I 131 monoclonal antibody 8H9

Indicates status has not been verified in more than two years